Display options
Cite
Rabijewski M, Zgliczyński W. Stosowanie DHEA u mezczyzn z koronograficznie potwierdzona choroba wieńcowa: wpływ na stezenia inhibitora aktywatora plazminogenu (PAI-1), tkankowego aktywatora plazminogenu (tPA) oraz fibrynogenu. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynol Pol. 2007;58(3):213-9
Rabijewski, M., & Zgliczyński, W. (2007). Stosowanie DHEA u mezczyzn z koronograficznie potwierdzona choroba wieńcowa: wpływ na stezenia inhibitora aktywatora plazminogenu (PAI-1), tkankowego aktywatora plazminogenu (tPA) oraz fibrynogenu. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynologia Polska, 58(3), 213-9.
Rabijewski, Michał, and Zgliczyński, Wojciech. "Stosowanie DHEA u mezczyzn z koronograficznie potwierdzona choroba wieńcowa: wpływ na stezenia inhibitora aktywatora plazminogenu (PAI-1), tkankowego aktywatora plazminogenu (tPA) oraz fibrynogenu." [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynologia Polska vol. 58,3 (2007): 213-9.
Rabijewski M, Zgliczyński W. Stosowanie DHEA u mezczyzn z koronograficznie potwierdzona choroba wieńcowa: wpływ na stezenia inhibitora aktywatora plazminogenu (PAI-1), tkankowego aktywatora plazminogenu (tPA) oraz fibrynogenu. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynol Pol. 2007 May-Jun;58(3):213-9. Polish. PMID: 17940987.
Copy Download .nbib Format: NLM
Share it on

Endokrynol Pol. 2007 May-Jun;58(3):213-9.

[Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].

Endokrynologia Polska

[Article in Polish]
Michał Rabijewski, Wojciech Zgliczyński

Affiliations

  1. Klinika Endokrynologii, Centrum Medycznego Kszta?cenia Podyplomowego, Warszawa. [email protected]

PMID: 17940987

Abstract

INTRODUCTION: The aim of this study was to analyze the influence of DHEA therapy on fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations in men with decreased serum DHEA-S levels and angiographically verified coronary heart disease (CHD).

MATERIAL AND METHODS: The study included thirty men aged 41-60 years (mean age 52 +/- 0.90 yr) with serum DHEA-S concentration < 2000 mg/l, who were randomized into a double-blind, placebo-controlled, cross-over trial. Subjects completed the 80 days study of 40 days of 150 mg oral DHEA daily or placebo, and next groups were changed after 30 days of wash-out. Fasting early morning blood samples were obtained at baseline and after each treatment to determine serum hormones levels (testosterone, DHEA-S, LH, FSH and estradiol) and also fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations.

RESULTS: Administration of DHEA was associated with 4.5-fold increase in DHEA-S levels. Estrogen levels significantly increased after DHEA from 22.1 +/- 0.7 pg/ml to 26.4 +/- 1.6 pg/l (mean +/- SEM; p < 0.05), while testosterone levels did not changed. Fibrinogen concentrations significantly decreased in DHEA group from 4.5 +/- 0.3 g/l to 3.83 +/- 0.2 g/l (p < 0.05 vs. placebo). Changes of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were not statistical significant (respectively: 8.37 +/- 0.4 ng/ml vs. 8.93 +/- 0.5 ng/ml and 82.3 +/- 6.3 ng/ml vs. 92.7 +/- 9.1 ng/ml (mean +/- SEM; NS vs. placebo). Tolerance of the treatment was good and no adverse effects were observed.

CONCLUSIONS: DHEA therapy in dose of 150 mg daily during 40 days in men with DHEAS levels < 2000 mg/l and angiographically verified coronary heart disease (CHD) was connected with significant decreasing of fibrinogen concentration and increasing of estradiol levels, and did not influence on plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations.

Substances

MeSH terms

Publication Types